Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell.
BACKGROUND
MC(T) and MC(TC) types of human mast cells (MCs) are distinguished from one another on the basis of the protease compositions of their secretory granules, but their functional and developmental relationships have been uncertain.


OBJECTIVE
These studies better define the functional properties and developmental relationship of MC(T) and MC(TC) cells.


METHODS
Mast cells were dispersed from human skin and lung, purified with anti-Kit antibody, and separated into CD88+ and CD88- populations by cell sorting. These cells were evaluated by immunocytochemistry with antitryptase and antichymase mAbs; for chymase and tryptase mRNA by real-time RT-PCR; for conversion of MC(T) to MC(TC) cells during cell culture with recombinant human stem cell factor and recombinant human IL-6; and for degranulation and leukotriene C 4 (LTC 4 ) secretion when stimulated with anti-FcepsilonRI, substance P, C5a, and compound 48/80.


RESULTS
Mature MC(T) and MC(TC) cells were separated from one another on the basis of selective expression of CD88, the C5aR, on MC(TC) cells. Lung MC(T) cells had negligible levels of chymase mRNA and retained their MC(T) phenotype in culture. Mature MC(TC) cells from skin and lung degranulated in response to FcepsilonRI cross-linking, C5a, compound 48/80, and substance P. Lung MC(TC) cells released LTC 4 on activation, but no LTC 4 was detected when skin-derived MC(TC) cells were activated. MC(T) cells from lung degranulated and released LTC 4 in response to anti-FcepsilonRI and substance P, but not to C5a and compound 48/80.


CONCLUSIONS
These observations functionally distinguish MC(T) from MC(TC) types of human mast cells and suggest important differences that may affect their participation in diseases such as asthma and urticaria.
Oskeritzian
Carole A
CA
Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Zhao
Wei
W
Min
Hae-Ki
HK
Xia
Han-Zhang
HZ
Pozez
Andrea
A
Kiev
Jonathan
J
Schwartz
Lawrence B
LB
D015550:Cell Degranulation / Q000187:drug effects; D002469:Cell Separation; D002478:Cells, Cultured; D053818:Chymases; D015936:Complement C5a / Q000494:pharmacology; D006801:Humans; D017997:Leukotriene C4 / Q000096:biosynthesis; D008168:Lung / Q000276:immunology*; D008407:Mast Cells / Q000145:classification / Q000276:immunology*; D012333:RNA, Messenger / Q000032:analysis; D044087:Receptor, Anaphylatoxin C5a / Q000032:analysis* / Q000172:deficiency; D017455:Receptors, IgE; D012697:Serine Endopeptidases / Q000032:analysis / Q000235:genetics; D012867:Skin / Q000276:immunology; D013373:Substance P / Q000494:pharmacology; D053802:Tryptases; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D012333:RNA, Messenger; D044087:Receptor, Anaphylatoxin C5a; D017455:Receptors, IgE; D017997:Leukotriene C4; D013373:Substance P; D003189:p-Methoxy-N-methylphenethylamine; D015936:Complement C5a; D012697:Serine Endopeptidases; D053818:Chymases; D053802:Tryptases